Effect of temperature on free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A concentration

Ultrasound in Obstetrics and Gynecology

Volumn 36, Issue 2, 2010, Pages 141-146

  Cruz, J ^a,b   Cruz, G ^a   Minekawa, R ^a   Maiz, N ^a,c   Nicolaides, K H ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c Centro Sanitario Virgen Del Pilar   (Spain)

Author keywords

First trimester combined screening; Free hCG; Nuchal translucency; PAPP A; Trisomy 21

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BLOOD; CHEMISTRY; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; LABORATORY DIAGNOSIS; MASS SCREENING; METHODOLOGY; PREGNANCY; PROTEIN STABILITY; TEMPERATURE;

ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROTEIN STABILITY; SPECIMEN HANDLING; TEMPERATURE;

EID: 77956158737     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.7688     Document Type: Article

References (11)

1. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346.
2. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008; 31: 618-624.
3. Stevenson HP, Leslie H, Sheridan B. Serum free β-human chorionic gonadotropin concentrations increase in unseparated blood specimens. Ann Clin Biochem 1993; 30: 99-100.
4. Wald NJ, Densem JW, Stone R, Cheng R. The use of free β- hCG in antenatal screening for Down syndrome. Br J Obstet Gynaecol 1993; 100: 550-557.
5. Beaman JM, Akhtar N, Goldie DJ. Down's syndrome screening using free beta hCG can significantly increase the Down's risk estimate. Ann Clin Biochem 1996; 33: 525-529.
6. Spencer K, Macri JN, Carpenter P, Anderson R, Krantz DA. Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood and dried whole blood filter-paper spots: impact on screening for Down's syndrome by measurement of free β-hCG subunit. Clin Chem 1993; 39: 1064-1068.
7. Sancken U, Bahner B. The effects of thermal instability of intact human chorionic gonadotropin (ihCG) on the application of its free beta-subunit (free beta-hcg) as a serum marker in Down syndrome screening. Prenat Diagn 1995; 15: 731-738.
8. Zimmermann R, Keller PJ, Huch A. Increased maternal serum free β-human chorionic gonadotropin concentrations in Down's pregnancies: an artefactual finding? Br J Obstet Gynaecol 1994; 101: 257-258.
9. Kardana A, Cole LA. The stability of hCG and free beta subunit in serum samples. Prenat Diagn 1997; 17: 141-147.
10. Cowans NJ, Stamatopoulou A, Hellstrom J, Makela M-M, Spencer K. PAPP-A and free β-hCG stability in first trimester serum using PerkinElmer AutoDELFIAR and DELFIAR Xpress systems. Prenat Diagn 2010; 30: 127-132.
11. Cuckle HS, Jones RG. Posting maternal blood samples for free β-human chorionic gonadotropin testing. Prenat Diagn 1995; 15: 879-880.